Harbour Investments Inc. grew its holdings in shares of Danaher Co. (NYSE:DHR – Free Report) by 3.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,531 shares of the conglomerate’s stock after acquiring an additional 45 shares during the quarter. Harbour Investments Inc.’s holdings in Danaher were worth $426,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of DHR. Benjamin Edwards Inc. lifted its stake in shares of Danaher by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC raised its holdings in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. lifted its position in shares of Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares in the last quarter. Trust Co of Kansas boosted its stake in shares of Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after acquiring an additional 40 shares during the period. Finally, Abacus Planning Group Inc. grew its position in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after purchasing an additional 40 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Danaher
In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.10% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Get Our Latest Analysis on DHR
Danaher Stock Down 3.7 %
Shares of NYSE:DHR opened at $230.50 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a 50 day simple moving average of $262.20 and a two-hundred day simple moving average of $260.38. Danaher Co. has a 1 year low of $206.30 and a 1 year high of $281.70. The firm has a market capitalization of $166.49 billion, a PE ratio of 43.99, a price-to-earnings-growth ratio of 4.44 and a beta of 0.85.
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the company posted $2.02 EPS. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities analysts predict that Danaher Co. will post 7.51 EPS for the current year.
Danaher Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. Danaher’s payout ratio is 20.61%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Comparing and Trading High PE Ratio Stocks
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to Buy Cheap Stocks Step by Step
- Time to Load Up on Home Builders?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.